Table 1.
Proposal as to which platforms are now ready for “prime time” according to AML disease subtype and clinical context
*Validated in large studies within clinical trials.
†Investigational.
‡Proportion of AML cases informative for a leukemia-specific molecular marker suitable for detection by RT-qPCR (ie, fusion gene, NPM1 mutation) varies according to age (see Figure 3).
§Some supportive data, but not ready for “prime time.”
